Bioregenx, Inc. (OTC: BRGX)

BioRegenx, Inc. is a Nevada-based company focused on the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies. Operating at the intersection of healthcare and technology, the company leverages artificial intelligence and proprietary biomedical solutions to address microvascular health, preventive care, and remote diagnostics. Its portfolio includes patented dietary supplements, Class I medical devices, and AI-driven diagnostic platforms, positioning it within the broader health and wellness industry. The company also maintains a digital presence through its social media and content management platforms, though these remain secondary to its core biomedical operations.

BioRegenx, Inc. generates revenue primarily through the sale of its dietary supplements, medical devices, and software licensing. Its flagship supplement, Endocalyx Pro™, targets microvascular health and is distributed through medical wholesalers, resellers, and direct-to-consumer channels. The GlycoCheck™ system, a Class I medical device paired with proprietary software, is sold to academic research institutions, hospitals, and wellness practitioners, often under subscription-based models that include recurring revenue from scans. Additionally, the company earns licensing fees from its AI-driven diagnostic technology, such as the DocSun AI Engine, which is integrated into third-party applications and platforms. While some revenue streams are established, others, including app-based diagnostics and telehealth solutions, remain in development with no material income reported to date.

The company operates through the following segments:

• DocSun BioMedical Holdings, Inc.: This segment specializes in contactless diagnostic technologies, combining ballistocardiography, photoplethysmography, and optical coherence tomography into the DocSun AI Engine. The technology enables non-invasive vital sign monitoring and is licensed to third parties for integration into applications such as fleet management, electric vehicles, and telehealth platforms. DocSun also collaborates with partners to develop mobile apps, including TruScan. Ai, which leverages its AI engine for health and wellness tracking. Revenue is derived from licensing agreements and potential future sales of software development kits.

• Microvascular Health Solutions™ LLC: This segment focuses on the research, development, and commercialization of microvascular health products, including the patented Endocalyx Pro™ dietary supplement and the GlycoCheck™ software and medical device. Endocalyx Pro™ is marketed as a supplement to support capillary health, while GlycoCheck™ is sold to academic researchers, healthcare practitioners, and wellness centers. The segment also engages in clinical studies to validate product efficacy and compliance with regulatory standards.

• MyBodyRx, LLC: A sales and product development subsidiary, MyBodyRx produces dietary supplements designed to complement Endocalyx Pro™ and promote healthy aging. Products are manufactured by accredited third-party facilities and distributed through direct-to-consumer and wholesale channels. The segment operates synergistically with Microvascular Health Solutions to expand the company’s supplement portfolio.

• NuLife Sciences™, Inc.: This segment functions as a marketing and distribution arm for the company’s health and wellness products, including Endocalyx Pro™, GlycoCheck™, and other devices such as pulsed electromagnetic field therapy systems. NuLife also develops health and wellness applications, including the VitalWellness app, which integrates DNA and epigenetics testing with AI-driven diagnostics. Revenue is generated through direct sales to practitioners, consumers, and wholesale distributors.

• Findit AI Connect, Inc.: This subsidiary operates Findit.com and Classworx.com, platforms that provide social media content management and search engine services. The segment aims to monetize through online content marketing, automation tools for affiliate partners, and third-party licensing. While currently non-revenue-generating, the company plans to enhance its AI capabilities to improve user engagement and search functionality.

BioRegenx, Inc. operates in highly competitive sectors, including dietary supplements, medical devices, telehealth, and digital marketing. Its primary competitors include well-established firms with significantly greater financial and operational resources, such as Alphabet Inc., Microsoft Corporation, and Meta Platforms in the digital space, and pharmaceutical and wellness companies in the health sector. The company’s competitive advantages lie in its proprietary technologies, including the DocSun AI Engine and GlycoCheck™ system, which offer unique, non-invasive diagnostic capabilities. Its patented Endocalyx Pro™ supplement also differentiates it within the preventive health market. However, the company faces challenges in scaling its operations, achieving regulatory compliance, and competing with larger incumbents in both the healthcare and digital advertising industries. Its focus on preventive healthcare and AI-driven diagnostics aligns with industry trends, but market acceptance and execution remain critical to its long-term positioning.

The company serves a diverse customer base, including academic research institutions, healthcare practitioners, hospitals, pharmacies, and individual consumers. Its GlycoCheck™ system is primarily sold to medical professionals and researchers, while Endocalyx Pro™ and other dietary supplements are distributed through medical wholesalers, resellers, and direct-to-consumer channels. NuLife Sciences targets doctors, wellness practitioners, and patients through its network of affiliates and online platforms such as Amazon and Walmart. DocSun’s AI technology is licensed to software developers and automotive manufacturers, with potential applications in fleet management and electric vehicles. The Findit.com platform caters to businesses and individuals seeking content management and search engine optimization services.